title: 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?
abstract: DOTATATE-based radionuclides have added new options in the diagnosis and treatment of meningiomas; however, a reliable predictor of tumor growth has still not been established.
  
  
  
  We analyzed 64 meningiomas imaged with (68)Ga-DOTATATE PET. Tumor growth rates were calculated by volumetric analysis of sequential MRI scans. Maximums of standardized uptake values (SUVmax) were correlated with tumor growth and covariates.
  
  
  
  World Health Organization (WHO) grades I and II meningiomas showed a correlation of SUVmax and tumor growth rate (meningiomas limited to the intracranial compartment: r = 0.757, P < .001, and transosseous growing meningiomas: r = 0.819, P = .024). SUVmax was significantly higher and the slope of the linear regression significantly steeper in transosseous compared with intracranial meningiomas (both P < .001). The association remained significant in multivariate analysis, and the prediction of tumor growth rate was independent of WHO grade. Anaplastic meningiomas showed no significant correlation of SUVmax and tumor growth.
  
  
  
  (68)Ga-DOTATATE PET is a reliable predictor of tumor growth in WHO grades I and II meningiomas and provides additional information to conventional cross-sectional imaging modalities. Hence, (68)Ga-DOTATATE PET can assist in selecting the time point for treatment initiation. Furthermore, meningiomas with fast tumor growth and transosseous expansion elicit the highest DOTATATE binding; therefore, they might be especially suited for DOTATATE-based therapy.
authors: Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland (M.S., A.B., N.S., F.P.K.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.S., M.W.); Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland (J.-K.B., N.K.); Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland (K.F., E.R.); Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland (N.S.); Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland (F.P.K.).
authors: Michael
authors: M
authors: Sommerauer
authors: Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland (M.S., A.B., N.S., F.P.K.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.S., M.W.); Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland (J.-K.B., N.K.); Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland (K.F., E.R.); Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland (N.S.); Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland (F.P.K.).
authors: Jan-Karl
authors: JK
authors: Burkhardt
authors: Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland (M.S., A.B., N.S., F.P.K.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.S., M.W.); Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland (J.-K.B., N.K.); Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland (K.F., E.R.); Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland (N.S.); Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland (F.P.K.).
authors: Karl
authors: K
authors: Frontzek
authors: Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland (M.S., A.B., N.S., F.P.K.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.S., M.W.); Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland (J.-K.B., N.K.); Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland (K.F., E.R.); Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland (N.S.); Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland (F.P.K.).
authors: Elisabeth
authors: E
authors: Rushing
authors: Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland (M.S., A.B., N.S., F.P.K.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.S., M.W.); Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland (J.-K.B., N.K.); Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland (K.F., E.R.); Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland (N.S.); Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland (F.P.K.).
authors: Alfred
authors: A
authors: Buck
authors: Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland (M.S., A.B., N.S., F.P.K.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.S., M.W.); Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland (J.-K.B., N.K.); Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland (K.F., E.R.); Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland (N.S.); Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland (F.P.K.).
authors: Niklaus
authors: N
authors: Krayenbuehl
authors: Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland (M.S., A.B., N.S., F.P.K.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.S., M.W.); Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland (J.-K.B., N.K.); Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland (K.F., E.R.); Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland (N.S.); Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland (F.P.K.).
authors: Michael
authors: M
authors: Weller
authors: Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland (M.S., A.B., N.S., F.P.K.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.S., M.W.); Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland (J.-K.B., N.K.); Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland (K.F., E.R.); Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland (N.S.); Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland (F.P.K.).
authors: Niklaus
authors: N
authors: Schaefer
authors: Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland (M.S., A.B., N.S., F.P.K.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.S., M.W.); Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland (J.-K.B., N.K.); Department of Neuropathology, University Hospital Zurich, Zurich, Switzerland (K.F., E.R.); Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland (N.S.); Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland (F.P.K.).
authors: Felix P
authors: FP
authors: Kuhn
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008577:Meningeal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008579:Meningioma / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods; D015282:Octreotide / Q000627:therapeutic use; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests
chemical_list: D015282:Octreotide
keywords: DOTATATE-PET; DOTATOC-PET; SSTR2; meningioma